Cargando…

Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report

BACKGROUND: Tirofiban is a nonpeptide glycoprotein IIb/IIIa receptor antagonist used widely in patients subjected to percutaneous coronary intervention. While the usage of tirofiban sets an important clinical benefit, severe thrombocytopenia can occur with use of this agent. CASE PRESENTATION: A 76-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ze-Mu, Wang, Bin, Li, Ya-Fei, Chen, Bei, Shen, Qin, Li, Dian-Fu, Wang, Lian-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576886/ https://www.ncbi.nlm.nih.gov/pubmed/37838704 http://dx.doi.org/10.1186/s13256-023-04169-5

Ejemplares similares

Tirofiban: A Rare Cause of Thrombocytopenia in a Patient Undergoing Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Tirofiban-induced thrombocytopenia
por: Wang, Jun, et al.
Publicado: (2023)

Influence of Tirofiban maintenance duration on patients with acute myocardial infarction treated by percutaneous coronary intervention
por: Ji, Zhen-Guo, et al.
Publicado: (2015)

Severe thrombocytopenia following tirofiban infusion
por: Panduranga, Prashanth, et al.
Publicado: (2011)

Case report: reuse of tirofiban leads to very severe thrombocytopenia
por: Li, Yuqing, et al.
Publicado: (2023)

A Simple Clinical Pre-procedure Risk Model for Predicting Thrombocytopenia Associated With Periprocedural Use of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention
por: Yi, Yi-Hu, et al.
Publicado: (2018)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Intracoronary administration of tirofiban during percutaneous coronary intervention facilitates patients with acute coronary syndrome
por: Jia, Helei, et al.
Publicado: (2017)

Tirofiban-Induced Thrombocytopenia Occurring with Crohn's Disease
por: Ibrahim, Toni, et al.
Publicado: (2016)

The effects of Anisodamine-Tirofiban Combined Therapy in acute myocardial infarction treated with Percutaneous Coronary Intervention (PCI)
por: Jiao, Yan, et al.
Publicado: (2022)

Tirofiban Induced Thrombocytopenia: A Rare but Severe Adverse Effect
por: Rawala, Muhammad Shabbir, et al.
Publicado: (2020)

Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention
por: Wang, Haixia, et al.
Publicado: (2020)

Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban
por: Campo, Gianluca, et al.
Publicado: (2010)

Severe Acute Thrombocytopenia After Treatment with Tirofiban: A Case Series Approach
por: Jiménez-Rodríguez, Gian-Manuel, et al.
Publicado: (2023)

Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention
por: Chen, Zhongxiu, et al.
Publicado: (2021)

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
por: Hu, Sigan, et al.
Publicado: (2018)

Acute Serious Thrombocytopenia Associated with Intracoronary Tirofiban Use for Primary Angioplasty
por: Yurtdaş, Mustafa, et al.
Publicado: (2014)

A case report of acute myocardial infarction with extremely severe thrombocytopenia after percutaneous coronary intervention
por: Chen, Shuai, et al.
Publicado: (2023)

Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention
por: Li, Lan, et al.
Publicado: (2017)

Contrast-induced thrombocytopenia following percutaneous coronary intervention
por: Ferreira, Roberto Muniz, et al.
Publicado: (2017)

Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials
por: Tang, Xiuying, et al.
Publicado: (2015)

The Effects of Ticagrelor Combined with Tirofiban on Coagulation Function, Serum Myocardial Injury Markers, and Inflammatory Factor Levels in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention
por: Li, Fang, et al.
Publicado: (2022)

The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function
por: Peng, Rui, et al.
Publicado: (2022)

Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial
por: Lee, Wonjae, et al.
Publicado: (2018)

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study
por: Lago, Igor Matos, et al.
Publicado: (2016)

Predictive value of the age, creatinine and ejection fraction score in patients undergoing primary percutaneous coronary intervention with bail-out tirofiban therapy
por: Ösken, Altuğ, et al.
Publicado: (2021)

Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention
por: Kang, Shi-xin, et al.
Publicado: (2022)

Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion
por: Li, Xiaoye, et al.
Publicado: (2019)

Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention
por: Kupó, Péter, et al.
Publicado: (2016)

Intravenous tirofiban therapy for patients with capsular warning syndrome
por: Li, Wei, et al.
Publicado: (2019)

Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry
por: Rigattieri, Stefano, et al.
Publicado: (2022)

A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion
por: Meghrajani, Vineet, et al.
Publicado: (2018)

Effects of Intracoronary Pro-urokinase or Tirofiban on Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Multi-Center, Placebo-Controlled, Single-Blind, Randomized Clinical Trial
por: Huang, Dong, et al.
Publicado: (2021)

Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis
por: Zhang, Yan, et al.
Publicado: (2022)

Association of thrombocytopenia and infection in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention
por: Wang, Litao, et al.
Publicado: (2021)

Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Tian, Rui, et al.
Publicado: (2023)

Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study
por: Kim, Yong-Won, et al.
Publicado: (2020)

Effects of Baseline Thrombocytopenia on In-hospital Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Shiraishi, Jun, et al.
Publicado: (2019)

Effects of bilirubin on perioperative myocardial infarction and its long-term prognosis in patients undergoing percutaneous coronary intervention
por: Li, Ya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_06medk9apj0mgh252gfeiqdl7s